Scinai Immunotherapeutics Ltd 6-K, filed Feb 2, 2021

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of February 2021

Commission File Number: 001-37353

BIONDVAXPHARMACEUTICALS LTD.

(Translation of registrant’s name into English)

JerusalemBioPark, 2nd Floor

HadassahEin Kerem Campus

Jeusalem,Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

On February 2, 2021, BiondVax Pharmaceuticals Ltd. announced closing of $12.1 million follow-on offering.

Exhibit Index

Exhibit 99.1 is hereby incorporated by reference into the Company's Registration Statement on Form S-8 (Registration No. 333-239344).

| 1 |

| --- |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

2

Exhibit 99.1

BiondVaxAnnounces Closing of $12.1 Million Follow-on Underwritten Offering

Jerusalem, Israel – February 2, 2021 – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today announced the closing of its previously announced underwritten offering. The total number of American Depositary Shares (“ADS”) sold by the Company was 2,434,783, each ADS representing forty (40) of its ordinary shares, at a public offering price of $4.95 per ADS, for gross proceeds to the Company of approximately $12.1 million, before deducting underwriting discounts and other offering expenses.

In connection with the offering, the Company has also granted the underwriters a 30-day option to purchase up to an additional 15% of the number of ADSs offered to the public at the public offering price, less underwriting discount, for covering over-allotments, if any. If the over-allotment option is exercised in full it would increase the total gross proceeds of the offering to approximately $13.8 million.

AegisCapital Corp. acted as sole bookrunning manager for the offering.

BiondVax intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, for general corporate purposes, which may include working capital, research and development activities, regulatory matters, capital investment or other related purposes. The Company may also use a portion of the net proceeds to in-license, invest in or acquire businesses, assets or technologies that BiondVax believes are complementary to its business focus, although BiondVax has no current commitments or agreements in those regards.

The ADSs described above were offered by the Company pursuant to a registration statement that was previously filed with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on August 10, 2020. A prospectus supplement and accompanying base prospectus relating to and describing the final terms of the offering are available on the SEC’s website located at www.sec.gov or from Aegis Capital Corp., Attention: Syndicate Department, 810 7th Avenue, 18th Floor, New York, NY 10019, by email at syndicate@aegiscap.com, or by telephone at (212) 813-1010.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

AboutBiondVax

BiondVaxPharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses. The Company had been developing M-001, a novel influenza vaccine candidate that was designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials designed to test for immunogenicity, the Company was able to demonstrate M-001 was effective in stimulating an immune response to a broad range of influenza virus strains. In October 2020, the Company completed a Phase 3 clinical trial of M-001 which failed to meet the trial’s primary and secondary efficacy endpoints. The company is now pursuing opportunities in the infectious disease space, including exploring several alternatives for development of a pipeline of assets.

ContactDetails

Joshua E. Phillipson | +972 8 930 2529 | j.phillipson@biondvax.com

ForwardLooking Statements

Thispress release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words suchas “expect,” “believe,” “intend,” “plan,” “continue,” “may,”“will,” “anticipate,” and similar expressions are intended to identify forward-looking statements, includingstatements regarding future business strategies that BiondVax may explore. These forward-looking statements reflect management’scurrent views with respect to certain current and future events and are subject to various risks, uncertainties and assumptionsthat could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risksand uncertainties include, but are not limited to, the risk that BiondVax may not be able to secure capital on attractive terms,if at all; the risk that BiondVax is currently exploring new business strategies after its M-001 universal influenza vaccine candidatefailed to meet the trial’s primary and secondary efficacy endpoints; the risk that the European Investment Bank may acceleratethe loans under its finance contract with BiondVax; the risk that BiondVax may not execute a strategic alternative to M-001; risksrelating to the COVID-19 (coronavirus) pandemic; BiondVax’s ability to acquire rights to additional product opportunities;BiondVax’s ability to enter into collaborations on terms acceptable to BiondVax or at all;  timing of receipt of regulatoryapproval of BiondVax’s manufacturing facility in Jerusalem, if at all or when required; and the risk that drug developmentinvolves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertaintiesaffecting the Company is contained under the heading “Risk Factors” in our prospectus supplement, which is availableon the SEC’s website, www.sec.gov. BiondVax undertakes no obligation to revise or update any forward-looking statement forany reason.

###